Form 8-K - Current report:
SEC Accession No. 0001725160-25-000108
Filing Date
2025-05-20
Accepted
2025-05-20 06:01:40
Documents
13
Period of Report
2025-05-20
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20250520.htm   iXBRL 8-K 33124
  Complete submission text file 0001725160-25-000108.txt   163174

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20250520.xsd EX-101.SCH 2039
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT zntl-20250520_def.xml EX-101.DEF 2834
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20250520_lab.xml EX-101.LAB 24316
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20250520_pre.xml EX-101.PRE 14660
15 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20250520_htm.xml XML 2835
Mailing Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (858) 263-4333
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

EIN.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 25966063
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)